Capricor Therapeutics (NASDAQ:CAPR) Shares Up 5.6% – Time to Buy?

Capricor Therapeutics Inc (NASDAQ:CAPR) shares rose 5.6% during trading on Monday . The stock traded as high as $13.80 and last traded at $13.80. Approximately 460,344 shares traded hands during trading, a decline of 62% from the average daily volume of 1,196,887 shares. The stock had previously closed at $13.07.

Analyst Ratings Changes

Several equities research analysts have issued reports on CAPR shares. Oppenheimer reiterated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Cantor Fitzgerald lifted their target price on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Maxim Group increased their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. HC Wainwright reaffirmed a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a research report on Thursday, November 14th. Finally, Piper Sandler assumed coverage on Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Price Performance

The company has a market capitalization of $637.03 million, a price-to-earnings ratio of -13.22 and a beta of 3.98. The stock has a 50-day moving average price of $17.68 and a 200-day moving average price of $10.46.

Hedge Funds Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CAPR. State Street Corp lifted its stake in shares of Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after buying an additional 111,291 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Capricor Therapeutics during the third quarter worth approximately $3,806,000. PFM Health Sciences LP bought a new stake in shares of Capricor Therapeutics during the third quarter worth approximately $2,324,000. Renaissance Technologies LLC boosted its holdings in shares of Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after acquiring an additional 84,350 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Capricor Therapeutics in the second quarter valued at approximately $426,000. 21.68% of the stock is owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.